Skip to main content

Should we increase the sugar tax?


I am often criticised for politicising medicine. Some people believe that medicine and politics shouldn’t mix. However, as soon as you realise that social determinants are the best predictor of clinical outcomes in most diseases you realise medicine and its practice has to be politicised. How do we as individual healthcare practitioners change the social determinants of health outcomes without the help of politicians?


Obesity may be a lifestyle disease, but it is clear that most people who are obese can’t help it. In other words, they are obese because of their circumstances.

“But people’s ability to take personal responsibility is shaped by their circumstances. People cannot take responsibility if they cannot control what happens to them.” Michael G. Marmot, The Health Gap: The Challenge of an Unequal World

Obesity is a risk factor for many diseases including all-cause dementia and multiple sclerosis. This is why it is so important for us to think about ways to reduce obesity. I am convinced by the evidence that obesity is a relatively new disease that is linked to the current food environment and the metabolic chaos it causes. To change the diet of the population we need legislation. This is why it is heartening that the sugar tax, although in my opinion too low, is beginning to have a small impact on sugar consumption.

This study below compared trends in the volume of soft drinks purchased before and after the introduction of the sugar tax. Although soft drink volumes purchased did not change, the amount of sugar in those drinks was 30 g, or 10%, lower per household per week after the tax. Although this is only a very modest reduction in sugar consumption, it is a small step in the right direction. Do you agree?

Now, what else can be done outside of the taxation system to reduce sugar consumption?


Fig 3

Observed and modelled amount of sugar in drinks liable to the Soft Drinks Industry Levy and confectionery purchased by each household weekly, March 2014 to March 2019. Points are observed data; coloured lines are modelled data; the first vertical line indicates the announcement of the SDIL; the second vertical line indicates the implementation of the SDIL; the Y-axis varies in scale between panels to maximise the resolution of figures; modelled purchases are presented as smoothed lines, including averaged effects for seasonality and the impact of Christmas and January, and, for confectionery, Easter



Pell et al. Changes in soft drinks purchased by British households associated with the UK soft drinks industry levy: controlled interrupted time series analysis. BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n254 (Published 10 March 2021)

Objective: To determine changes in household purchases of drinks and confectionery one year after implementation of the UK soft drinks industry levy (SDIL).

Design: Controlled interrupted time series analysis.

Participants: Members of a panel of households reporting their purchasing on a weekly basis to a market research company (average weekly number of participants n=22 183), March 2014 to March 2019.

Intervention: A two-tiered tax levied on manufacturers of soft drinks, announced in March 2016 and implemented in April 2018. Drinks with ≥8 g sugar/100 mL (high tier) are taxed at £0.24/L and drinks with ≥5 to <8 g sugar/100 mL (low tier) are taxed at £0.18/L. Drinks with <5 g sugar/100 mL (no levy) are not taxed.

Main outcome measures: Absolute and relative differences in the volume of, and amount of sugar in, soft drinks categories, all soft drinks combined, alcohol, and confectionery purchased per household per week one year after implementation of the SDIL compared with trends before the announcement of the SDIL.

Results: In March 2019, compared with the counterfactual estimated from pre-announcement trends, purchased volume of drinks in the high levy tier decreased by 155 mL (95% confidence interval 240.5 to 69.5 mL) per household per week, equivalent to 44.3% (95% confidence interval 59.9% to 28.7%), and sugar purchased in these drinks decreased by 18.0 g (95% confidence interval 32.3 to 3.6 g), or 45.9% (68.8% to 22.9%). Purchases of low tier drinks decreased by 177.3 mL (225.3 to 129.3 mL) per household per week, or 85.9% (95.1% to 76.7%), with a 12.5 g (15.4 to 9.5 g) reduction in sugar in these drinks, equivalent to 86.2% (94.2% to 78.1%). Despite no overall change in volume of no levy drinks purchased, there was an increase in sugar purchased of 15.3 g (12.6 to 17.9 g) per household per week, equivalent to 166.4% (94.2% to 238.5%). When all soft drinks were combined, the volume of drinks purchased did not change, but sugar decreased by 29.5 g (55.8 to 3.1 g), or 9.8% (17.9% to 1.8%). Purchases of confectionery and alcoholic drinks did not change.

Conclusions: Compared with trends before the SDIL was announced, one year after implementation, the volume of soft drinks purchased did not change. The amount of sugar in those drinks was 30 g, or 10%, lower per household per week—equivalent to one 250 mL serving of a low tier drink per person per week. The SDIL might benefit public health without harming industry.

Trial registration: ISRCTN18042742.

CoImultiple

Twitter@gavinGiovannoni                         Medium: @gavin_24211

Comments

Popular posts from this blog

Moved to substack

Dear Reader We have moved the preventive neurology unit blog to a new platform called substack . Google is discontinuing its Feedburner and has not added many new features to blogger for some time, which is why we have decided to move the site.  https://preventiveneurology.substack.com/  Thanks Gavin Giovannoni

Are you ready for an EBV vaccine to prevent MS?

"Professor Giovannoni, you tell me that my daughter has a 1 in 40 chance of developing multiple sclerosis and that MS has reached epidemic proportions in parts of the world? Is there anything I can do to reduce her chances of getting MS? Is there anything we can do to stop other people from getting MS?" Although multiple sclerosis (MS) is a complex disease due to the interaction of genetic and environmental factors data on the occurrence of MS at the population level (epidemiology) supports the Epstein Barr Virus (EBV) as being necessary, but not sufficient, for someone to develop MS. In other words, EBV is probably the cause of MS. Of all the putative causative agents that have been proposed to be associated with MS, EBV is the only one where the risk of getting MS if you are EBV negative is close to zero or zero if you limit the analyses to those studies which use a technique called immunofluorescence microscopy as the gold-standard assay to detect anti-EBV antibodies. EBV

The Aducanumab shitstorm

Congratulations to  Al Sandrock , from Biogen, for never giving up on science and for being a  risk-taker extraordinaire .   Photo by Markus Winkler on Unsplash The FDA’s controversial approval of aducanumab for the treatment of Alzheimer’s disease on Monday has caused a shitstorm. The main reason is that in November the FDA’s independent advisory committee voted against recommending approval; they said the data failed to demonstrate persuasively that aducanumab slowed cognitive decline. In a NY Times article Dr Lon Schneider, director of the California Alzheimer’s Disease Center at the University of Southern California and one of the aducanumab site investigators said “This should not be approved, because substantial evidence of effectiveness hasn’t been shown and there’s very little potential that this will address the needs of patients.” What the FDA has done is use the so-called Accelerated Approval Pathway , which allows them to approve a drug for a serious or life-threatening